Physician profile
Daniel J Stein
NPI 1700968880
$226,868.03
in general payments reported to CMS, 2019-2025
13 companies · $15K in 2025
The $15K reported for 2025 was more than what 94% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $41K · 2020: $7,689 · 2021: $30K · 2022: $57K · 2023: $38K · 2024: $38K · 2025: $15K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $77K · Travel and Lodging: $6,907 · Food and Beverage: $3,927 · Consulting Fee: $3,000 · Education: $30.40.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $77,325.75 |
| Travel and Lodging | $6,906.87 |
| Food and Beverage | $3,927.11 |
| Consulting Fee | $3,000.00 |
| Education | $30.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $103,068.02 | 2019-2025 | Skyrizi, Rinvoq |
| E.R. Squibb & Sons, L.L.C. | $43,053.33 | 2021-2024 | Zeposia |
| Takeda Pharmaceuticals U.S.A., INC. | $31,977.12 | 2019-2025 | Entyvio |
| Lilly USA, LLC | $20,892.92 | 2023-2024 | Omvoh |
| Pfizer INC. | $9,752.58 | 2019-2024 | |
| Janssen Scientific Affairs, LLC | $7,990.03 | 2019 | |
| Allergan, INC. | $4,800.00 | 2019-2021 | |
| Janssen Biotech, INC. | $3,686.58 | 2019-2025 | Tremfya |
| Celgene Corporation | $1,365.22 | 2022-2024 | Zeposia |
| Cook Medical LLC | $282.23 | 2025 | Echotip Insight |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Stein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.